Franklin

Antibody-Drug Conjugates : Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer.

Author/Creator:
Olivier, Kenneth J., Jr.
Publication:
New York : John Wiley & Sons, Incorporated, 2016.
Format/Description:
Book
1 online resource (566 pages)
Status/Location:
Loading...

Options
Location Notes Your Loan Policy

Details

Other records:
Subjects:
Immunoconjugates.
Form/Genre:
Electronic books.
Contents:
Cover
Title Page
Copyright
Contents
List of Contributors
Preface
Historical Perspective: What Makes Antibody-Drug Conjugates Revolutionary?
Introduction
Early Work in Monoclonal Antibody Development: Ehrlich's Magic Bullets
Use of Monoclonal Antibodies to Identify and Treat Cancer
Linking Monoclonal Antibodies with Cytotoxic Agents
Antibody-Drug Conjugates in the Clinic
Why ADCs Are Revolutionary?
References
Part I 1 What is an Antibody-Drug Conjugate
Chapter 1 Typical Antibody-Drug Conjugates
1.1 Introduction
1.1.1 A Simple Concept
1.1.2 Turning Antibodies into Potent Anticancer Compounds
1.1.3 What is a Typical ADC and How Does it Act?
1.1.4 Simple Concept, but Not So Simple to Execute
1.2 The Building Blocks of a Typical ADC
1.2.1 The Antibody
1.2.1.1 Antibody Isotype in ADCs
1.2.1.2 Functional Activity of the Antibody Moiety in ADCs
1.2.2 The Payload
1.2.2.1 DNA-Targeting Payloads
1.2.2.2 Payloads Targeting Tubulin
1.2.3 Linker Chemistries
1.3 Building an ADC Molecule
1.3.1 Conjugation of Payloads to Antibodies at Lysine Residues
1.3.2 Conjugation of Payloads to Antibodies at Cysteine Residues
1.4 Attributes of a Typical ADC
1.4.1 Structural Attributes of a Typical ADC
1.4.2 Functional Characteristics of a Typical ADC
1.4.2.1 In Vitro Properties
1.4.2.2 In Vivo Efficacy
1.4.2.3 Pharmacokinetics of ADCs
1.5 Summary
Acknowledgment
References
Part II Engineering, Manufacturing, and Optimizing Antibody-Drug Conjugates
Chapter 2 Selecting Optimal Antibody-Drug Conjugate Targets Using Indication-Dependent or Indication-Independent Approaches
2.1 Characteristics of an Optimal ADC Target
2.2 Indication-Dependent ADC Target Selection
2.3 Indication-Independent ADC Target Selection.
2.4 Concluding Remarks and Future Directions
Acknowledgments
References
Chapter 3 Antibody-Drug Conjugates: An Overview of the CMC and Characterization Process
3.1 Introduction
3.2 ADC Manufacturing Process
3.2.1 Conjugation
3.2.2 Conjugation - Next‐Generation Chemistry
3.2.2.1 Conjugation - Novel Payloads
3.2.2.2 Conjugation - Linker Design
3.2.3 mAb Engineering
3.2.4 Purification
3.2.5 Formulation
3.3 Characterization
3.3.1 Quality and Stability Testing
3.3.2 Biochemical and Microbiological Testing
3.3.3 Extended Characterization
3.4 Comparability
3.5 Concluding Remarks
References
Chapter 4 Linker and Conjugation Technology
and Improvements
4.1 Overview
4.2 Noncleavable
4.3 Cleavable Linkers and Self-Immolative Groups
4.4 Differences in Therapeutic Window of Cleavable and Noncleavable Linkers
4.5 Improving Therapeutic Window with Next-Generation Linker Technologies
4.6 Site-Specific Conjugation, Homogeneous Drug Species, and Therapeutic Window
4.7 Influence of Linkers on Pharmacokinetics and ADME
4.8 PEG Linkers to Optimize Clearance, Solubility, and Potency
4.9 Linkers to Optimize for Drug Resistance
4.10 Improving Solid Tumor Penetration with Linkers
4.11 Analytical Methods for Characterizing Linker Pharmacodynamics
4.12 Conclusion
References
Chapter 5 Formulation and Stability
5.1 Introduction
5.2 Stability Considerations for ADCs
5.2.1 Physical Stability
5.2.2 Chemical Stability
5.3 Formulation Approaches
5.4 Logistical Considerations
5.5 Summary and Close
References
Chapter 6 QC Assay Development
6.1 Introduction
6.2 Drug-to-Antibody Ratio
6.3 Drug Loading Distribution
6.3.1 Lysine‐Linked ADCs
6.3.2 Cysteine‐Linked ADCs
6.4 Positional Isomers
6.5 ADC Concentration.
6.6 Drug-Related Substances
6.7 Antigen Binding Assays and Potential Impact of Drug Conjugation
6.8 Cell-Based Cytotoxicity Assays
6.9 Assays to Monitor Fc-Dependent Effector Functions to Characterize Additional Possible Mechanisms of Action
6.10 Immunogenicity Assays to Monitor the Immune Response to ADC
6.11 Conclusions
6.12 Key Guidance Documents
Acknowledgments
References
Chapter 7 Occupational Health and Safety Aspects of ADCs and Their Toxic Payloads
7.1 Introduction
7.2 Background on ADCs
7.2.1 Payloads
7.2.2 Linker Technologies
7.2.3 Antibodies
7.2.4 Partial Conjugates
7.3 Occupational Hazard Assessment of ADCs and Their Components
7.4 Occupational Implications and Uncertainties
7.4.1 Routes of Occupational Exposure
7.4.2 Binding Efficiency (Payload to Antibody)
7.4.3 Unintended Targets
7.4.4 Free Payload in Conjugation Formulation
7.4.5 Local Effects in the Lung
7.5 General Guidance for Material Handling
7.5.1 Handling of Powders
7.5.2 Handling of Solutions
7.6 Facility Features and Engineering Controls
7.6.1 HVAC and Air Pressure Relationships
7.6.2 Air Changes and Airflow
7.6.3 Recirculation and Filtration of Room Air
7.6.4 Changing Areas
7.6.5 Designated Areas
7.7 Specific Operational Guidance
7.7.1 Payload Synthesis
7.7.2 Conjugation
7.7.3 Lyophilization
7.7.4 Cleaning
7.8 Personal Protective Equipment
7.8.1 Chemical Protective Clothing
7.8.1.1 Protective Clothing
7.8.1.2 Gloves
7.8.1.3 Eye and Face Protection
7.8.2 Respiratory Protection
7.9 Training
7.9.1 Potent Compound Awareness Training
7.9.2 Standard Operating Procedures for Synthesizing and Handling ADCs
7.10 Industrial Hygiene Monitoring
7.10.1 Air Monitoring
7.10.2 Surface Monitoring
7.11 Medical Surveillance Program.
7.12 Summary and Future Direction
References
Part III Nonclinical Approaches
Chapter 8 Bioanalytical Strategies Enabling Successful ADC Translation
8.1 Introduction
8.2 ADC LC/MS Bioanalytical Strategies
8.2.1 Nonregulated Unconjugated Payload Bioanalysis
8.2.2 Intact Protein Bioanalysis by LC/MS: Measurement of Drug‐to‐Antibody Ratio
8.2.3 ADC Pharmacokinetic Bioanalysis by LC/MS
8.2.4 Calculated Conjugated Payload Determination
8.2.5 Conjugated Payload Quantitation of Cleavable Linker ADCs
8.2.6 Conjugated Payload Quantitation by Peptide‐Based Analysis
8.3 Non-Regulated ADC Pharmacokinetic and Immunogenicity Support Using Ligand Binding Assays
8.3.1 ADC Ligand Binding Assays
8.3.2 Reagents
8.3.3 ADC Reference Standards
8.3.4 Total Antibody Assays
8.3.5 ADC Assays
8.3.6 Target Interference in ADC Measurement
8.3.7 ADC Immunogenicity Assays
8.4 Biodistribution Assessment
8.5 Regulated ADC Pharmacokinetics and Immunogenicity Evaluation
8.5.1 ADC Assays in Regulated Studies
8.5.2 Regulated Ligand Binding Assays
8.5.3 Regulated LC/MS/MS Quantitation of Unconjugated Payload
8.5.4 Regulated Conjugated Payload LC/MS Assays
8.5.5 Regulated Anti‐therapeutic Assays
8.6 ADC Biomeasures and Biomarkers
8.7 Summary
References
Chapter 9 Nonclinical Pharmacology and Mechanistic Modeling of Antibody-Drug Conjugates in Support of Human Clinical Trials
9.1 Introduction
9.2 Cell Line Testing
9.2.1 Antigen Density
9.2.2 Antigen and Antibody-Drug Conjugate Internalization
9.2.3 Payload Processing and Binding
9.3 Xenograft Models
9.3.1 Payload Bystander Effects
9.3.2 Biomarker Assays
9.4 Nonclinical Testing to Support Investigational New Drug Applications
9.4.1 Antibody-Drug Conjugate Efficacious Dose Range.
9.5 Mechanistic Modeling of Antibody-Drug Conjugates
9.5.1 Tumor Tissue Transport Considerations
9.5.2 Subcellular Trafficking
9.5.3 Shed Antigen and Endosomal Processing
9.5.4 Enhanced Pharmacokinetic Modeling to Enable Antibody-Drug Conjugate Pharmacology Predictions
9.5.5 Mechanistic Modeling of Antibody-Drug Conjugate Pharmacology: Accounting for Uncertainties
9.6 Target-Mediated Toxicity of Antibody-Drug Conjugates
9.7 Considerations for Nonclinical Testing Beyond Antibody-Drug Conjugate Monotherapies
9.8 Summary
Acknowledgments
References
Chapter 10 Pharmacokinetics of Antibody-Drug Conjugates
10.1 Introduction
10.2 Pharmacokinetic Characteristics of an ADC
10.2.1 ADC Biodistribution
10.2.2 ADC Clearance
10.3 Unique Considerations for ADC Pharmacokinetics
10.3.1 Linker Stability
10.3.2 Site of Conjugation and Drug Load
10.3.3 Cytotoxic Drug
10.4 Tools to Characterize ADC PK/ADME
10.4.1 Bioanalytical Methods
10.4.2 In Vitro Assays
10.4.3 In Vivo Studies
10.4.4 Pharmacokinetic/Pharmacodynamic (PK/PD) Models
10.5 Utilization of ADC Pharmacokinetics to Optimize Design
10.6 Pharmacokinetics of Selected ADCs
10.6.1 Ado‐Trastuzumab Emtansine (Kadcyla®)
10.6.2 Brentuximab Vedotin (Adcetris®)
10.7 Summary
References
Chapter 11 Path to Market Approval: Regulatory Perspective of ADC Nonclinical Safety Assessments
11.1 Introduction
11.2 FDA Experience with ADCs
11.3 Regulatory Perspective of the Nonclinical Safety Assessment of ADCs
11.3.1 Regulatory Guidance Available for Nonclinical Studies
11.3.1.1 Species Selection
11.3.1.2 Study Duration and Dose Regimen
11.3.1.3 Study Test Article
11.3.1.4 Pharmacology Studies
11.3.1.5 Pharmacokinetics/Toxicokinetics
11.3.1.6 Genotoxicity
11.3.1.7 Developmental and Reproductive Toxicology.
11.3.1.8 First-in-Human Dose Selection.
Notes:
Description based on publisher supplied metadata and other sources.
Local notes:
Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2021. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.
Contributor:
Hurvitz, Sara A.
Other format:
Print version: Olivier, Kenneth J., Jr. Antibody-Drug Conjugates
ISBN:
9781119060802
9781119060680
OCLC:
964410742